CN1714793A - Famciclovir slow-releasing capsule for anti-virus treatment and its producing method - Google Patents
Famciclovir slow-releasing capsule for anti-virus treatment and its producing method Download PDFInfo
- Publication number
- CN1714793A CN1714793A CN 200410027929 CN200410027929A CN1714793A CN 1714793 A CN1714793 A CN 1714793A CN 200410027929 CN200410027929 CN 200410027929 CN 200410027929 A CN200410027929 A CN 200410027929A CN 1714793 A CN1714793 A CN 1714793A
- Authority
- CN
- China
- Prior art keywords
- famciclovir
- piller
- release
- weight
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 title claims abstract description 139
- 229960004396 famciclovir Drugs 0.000 title claims abstract description 138
- 239000002775 capsule Substances 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims description 6
- 230000002155 anti-virotic effect Effects 0.000 title 1
- 229920000642 polymer Polymers 0.000 claims abstract description 65
- 239000003814 drug Substances 0.000 claims abstract description 60
- 238000000576 coating method Methods 0.000 claims abstract description 54
- 239000011248 coating agent Substances 0.000 claims abstract description 50
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 19
- 239000008188 pellet Substances 0.000 claims abstract description 11
- 230000000968 intestinal effect Effects 0.000 claims abstract description 6
- 238000013268 sustained release Methods 0.000 claims description 57
- 239000012730 sustained-release form Substances 0.000 claims description 57
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 54
- 238000013270 controlled release Methods 0.000 claims description 40
- 239000010410 layer Substances 0.000 claims description 36
- 238000002360 preparation method Methods 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 35
- 239000002671 adjuvant Substances 0.000 claims description 28
- 238000005253 cladding Methods 0.000 claims description 27
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 27
- 235000019359 magnesium stearate Nutrition 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 25
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 25
- 239000011230 binding agent Substances 0.000 claims description 23
- 239000004925 Acrylic resin Substances 0.000 claims description 22
- DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical group [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 claims description 21
- 229930006000 Sucrose Natural products 0.000 claims description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 18
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 18
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 18
- 239000005720 sucrose Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 16
- 238000005507 spraying Methods 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 229960003943 hypromellose Drugs 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 11
- 239000001856 Ethyl cellulose Chemical group 0.000 claims description 10
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 10
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 10
- 229920001249 ethyl cellulose Chemical group 0.000 claims description 10
- 239000004014 plasticizer Substances 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 238000012946 outsourcing Methods 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- -1 phthalate ester Chemical class 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000005453 pelletization Methods 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000012055 enteric layer Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract 1
- 210000004051 gastric juice Anatomy 0.000 abstract 1
- 229920003176 water-insoluble polymer Polymers 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 208000002672 hepatitis B Diseases 0.000 description 11
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 10
- 229960001179 penciclovir Drugs 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- KGSIOVLUJYQLKR-UHFFFAOYSA-N [[4-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)butoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 KGSIOVLUJYQLKR-UHFFFAOYSA-N 0.000 description 7
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 4
- 229960001627 lamivudine Drugs 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000001069 triethyl citrate Substances 0.000 description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
- 235000013769 triethyl citrate Nutrition 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000003602 anti-herpes Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2-amino-9-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 229940123014 DNA polymerase inhibitor Drugs 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of slow-releasing famciclovir capsule for antiviral treatment, and features that the slow-releasing famciclovir capsule is prepared through coating famciclovir medicine with supplementary material to form the pellet core, coating the pellet core with inner release controlling layer of water insoluble polymer, re-coating with outer release controlling layer of enteric polymer to form release controlling famciclovir pellet, and encapsulating famciclovir pellet to form the slow-releasing famciclovir capsule. In artificial gastric juice and artificial intestinal juice, the slow-releasing famciclovir capsule has its medicine releasing degree of 10-30 %, 30-70 % and over 70 % separately in 1.5 hr, 3 hr and 8 hr. The pellet is measured to have medicine content of 56.8-65.2 %.
Description
Technical field
The present invention relates to a kind of famciclovir sustained-release capsule and production method thereof that is used for antiviral therapy.
Background technology
(famciclovir FCV) equals the acyclic nucleoside class antiviral drugs synthetic, that GSK (GlaxoSmithKline) company develops and put on market in 1994 in 1985 by Harnden to famciclovir, is the guanosine analog.Herpes simplex virus I-type (HSV-I), II type (HSV-II), varicella zoster virus (VZV) and hepatitis B virus (HBV) etc. are had inhibitory action, and its curative effect is better than acyclovir commonly used clinically at present when being used for the treatment of herpes zoster, herpes facialis and genital herpes clinically.The effect of its treatment hepatitis B also is subject to people's attention day by day, and at present, famciclovir is carrying out clinical research as the new drug of treatment chronic hepatitis B.
Famciclovir be penciclovir (penciclovir, precursor medicine PVC) are absorbed rapidly after oral, and relevant enzyme is sloughed two acetyl group in intestinal wall and liver, and with on its purine ring 6 be oxidized to ketone group, change into penciclovir.In HSV-I, HSV-II and VZV infection cell; penciclovir is earlier by viral distinctive thymidine kinase (ThymidineKinase; TK) single phosphorylated; the penciclovir phosplate (PCV-MP) that forms; further by host enzyme catalysis two phosphorylated and three phosphorylated being taken place successively, forms intravital active component penciclovir triphosphate (PCV-TP) more at last.PCV-TP is brought in the viral DNA chain by the wrong NSC 22837 for the treatment of as of viral DNA polymerase, the synthetic of viral DNA is suppressed, thereby the effect of anti-herpesvirus takes place.On the contrary, penciclovir does not almost have effect seldom by phosphorylation to human normal cell's archaeal dna polymerase in non-infected cell, and safety is good.The mechanism of the anti-HBV of famciclovir is machine-processed different with anti-herpesvirus, and its mechanism is still not fully aware of, but the active metabolite of the anti-HBV effect of performance in vivo also is PCV-TP.
Famciclovir has overcome the low defective of direct oral penciclovir bioavailability, and bioavailability is up to 77%, reaches maximum plasma concentration in about 1 hour.Studies show that its blood halflife is about 2 hours.And in virus infected cell, the half-life of PCV-TP is 10-12 hour.There is greatest differences in half-life in its blood halflife and the virus infected cell.
The famciclovir sheet of China's listing, treatment herpes zoster and primary genitalia herpes dosage are 250mg, 3 times on the one, 7 days courses of treatment; And in the clinical research of the use famciclovir sheet that my company is just carrying out treatment chronic viral hepatitis B, the patient needs medication every day 3 times, each 500mg, and the course of treatment is half a year at least.Because every day, medicining times was many, the course of treatment is long, can cause patient's drug compliance bad, occurs because of missing the situation of the unsatisfactory curative effect that causes easily.Therefore, the exploitation of famciclovir sustained-release preparation has bigger meaning, not only can reach required blood drug level, and the energy held stationary, and can improve patient's drug compliance, thereby makes medicine bring into play due curative effect.
Preclinical study shows that the active metabolite penciclovir of famciclovir reaches the effect that shows the inhibition virus replication on duck hepatitis B animal model to the HepG2.2.15 cell strain of In vitro culture.Trepo report in 1996 is used famciclovir and is treated 330 routine chronic hepatitis B patients, confirms that famciclovir can suppress hepatitis B virus (HBV) and duplicate.In recent years along with the application of internationally recognized anti-HBV medicine alpha-interferon and lamivudine (lamivudine) at present, the effective percentage that shows alpha-interferon treatment chronic hepatitis B is about 30%, relapse rate height after the drug withdrawal, lamivudine is a cytosine nucleoside analogs, it is HBV-DNA polymerase inhibitor, its the treatment chronic hepatitis B in the time of 1 year the HBV-DNA negative conversion rate can reach 80%, but the HbeAg negative conversion rate is only about 20%--30%, and bounce after the drug withdrawal, long-term prescription causes hepatitis B virus to morph, and produces drug resistance.Recent study shows that therapeutic alliance or sequential therapy ratio use single antiviral treatment hepatitis B effective.Also there are famciclovir and other drug to unite use, comprise the report that associating lamivudine, alpha-interferon use.Famciclovir not only has the HBV-DNA of inhibition and duplicates effect, also has the effect that suppresses covalently closed circular DNA (cccDNA) in the hepatocyte, and this cccDNA is the primary template of virus replication.The clinical research report of recurrence hepatitis B after the external existing 600 many cases famciclovirs prevention liver transplantation.
Behind the famciclovir tablet oral administration, blood drug level changes greatly, and no matter for independent antiviral therapy or combination antiviral therapy, this variation is all very unfavorable.There are 1.3 hundred million hepatitis B virus carrierss (comprising 3,000,000 chronic viral hepatitis B patients) in China, at the present situation that lacks treatment hepatitis B good medicine at present clinically, is necessary to develop the novel form of famciclovir.
The inventor notices: the blood halflife of PCV-TP is about 2 hours.And in virus infected cell, the half-life of PCV-TP is 10-12 hour.There is greatest differences in half-life in its blood halflife and the virus infected cell, is necessary famciclovir is made slow releasing capsule.
Summary of the invention
The purpose of this invention is to provide efficient, low toxicity, the patient uses the high a kind of famciclovir sustained-release capsule that is used for antiviral therapy of compliance.
Further purpose of the present invention provides the capsular production method of the famciclovir sustained-release that uses in antiviral therapy.
Above-mentioned purpose of the present invention adopts following technical scheme to be achieved:
A kind of famciclovir sustained-release capsule that is used for antiviral therapy, it is characterized in that: constitute the ball core with adjuvant piller outsourcing famciclovir medicine layer, outside medicine layer, constitute the controlled release internal layer of control drug release by insoluble polymer, outside described controlled release internal layer, the controlled release outer coating that cladding is made of enteric polymer, make the famciclovir sustained-release piller, described piller filling constitutes the famciclovir sustained-release capsule in capsule.
By making 1000 calculating of slow releasing capsule, it is composed as follows that various components account for the weight percent of total charges in the every mass of 1000 kernel 192-220g, capsule:
Each component accounts for the percentage by weight of total charges and is in the ball core:
Famciclovir 56.8%-65.2%
Sucrose (or microcrystalline Cellulose) 13.1%-15%
Starch 5.1%-5.8%
Micropowder silica gel 1.1%-1.3%
Polyvidone (or hypromellose) 2.5%-2.9%
Each component accounts for the percentage by weight of total charges and is in the controlled release internal layer:
Insoluble polymer (quaternary amine methacrylate PO or ethyl cellulose) 3.6%-7.9%
Polyethylene glycol 6000 0.36%-0.79%
Antiblocking agent (Pulvis Talci) 0.91%-1.98%
Magnesium stearate 0.91%-1.98%
Each component accounts for the percentage by weight of total charges and is in the controlled release outer coating:
Enteric polymer (polyacrylic resin II) 1.26%-2.75%
Enteric polymer (polyacrylic resin III) 1.26%-2.75%
Plasticizer (polyethylene glycol 6000) 0.25%-0.55%
Antiblocking agent (Pulvis Talci) 0.63%-1.36%
The magnesium stearate surplus
The capsular famciclovir sustained-release piller of famciclovir sustained-release is done medium with simulated gastric fluid, simulated intestinal fluid, and the release scope 1.5 hours, 3 hours and 8 hours is respectively: more than 10%-30%, the 30%-70% and 70%.
The famciclovir sustained-release capsule adopts the slow release form of present most popular coated pellets, has in the safety, body advantages such as release is stable.Coated pellets serves as the adjuvant piller of preparation famciclovir ball core with sucrose piller or microcrystalline Cellulose piller, and adjuvant piller diameter is 0.5-0.7mm.In centrifugal granulator, prepare the medicine piller with poudrage.The binding agent that preparation famciclovir ball core is selected is polyvidone or hypromellose.Binding agent is mixed with aqueous solution or organic solvent solution uses.
The controlled release internal layer polymer of cladding is selected quaternary amine methacrylate or ethyl cellulose outside famciclovir piller (ball core).Can adopt polymer to be dissolved in the solution of organic solvent or the aqueous dispersion of polymer.In order to suppress famciclovir sustained-release piller rate of releasing drug faster in acid medium, the present invention clads the enteric polymer as controlled release outer coating again outside the controlled release internal layer, these enteric polymer comprise methylmethacrylate copolymer, ethyl methacrylate copolymers or hypromellose phthalate ester.Coating carries out in fluid bed (end spray).
The cladding amount of polymer is the principal element of decision rate of releasing drug.In the slow-release pill preparation, the cladding amount of the polymer of selection generally can be the 3-25% (w/w) of medicine ball core weight.But coating solution prescription of the present invention and coating operating procedure parameter also have a significant impact the rate of releasing drug of slow-release pill.The cladding amount of polymer depends on whether the piller behind the coating reaches the release that target level of product quality is stipulated in the actual coating operation.
Add an amount of plasticizer in the coating solution, for example Polyethylene Glycol, triethyl citrate, dibutyl sebacate and diethyl phthalate etc., suitable consumption is the 5-30% of polymer (w/w).Also should add an amount of antiblocking agent in the coating solution, for example Pulvis Talci, micropowder silica gel, magnesium stearate and tristerin etc., suitable consumption is the 5%-100% of polymer (w/w).
A kind of capsular production method of famciclovir sustained-release that is used for antiviral therapy, it is characterized in that: constitute the ball core with adjuvant piller outsourcing famciclovir medicine layer, outside medicine layer, constitute the controlled release internal layer of control drug release by insoluble polymer, outside described controlled release internal layer, clad the controlled release outer coating that constitutes by enteric polymer again, make the famciclovir sustained-release piller, described piller filling constitutes the famciclovir sustained-release capsule in capsule.
In famciclovir piller (ball core) preparation: sucrose piller or microcrystalline Cellulose (0.5-0.7mm) 500 weight portions are placed centrifugal coating pelletizing machine, after the start, with 15 weight portions/minute speed spray 5% polyvidone alcoholic solution, 1200 weight portions, simultaneously with 20 weight portions/minute speed be sprinkled into famciclovir powder 1500-1600 weight portion, the medicine piller that makes was placed 50 ℃ of baking ovens dry 4 hours;
In the preparation of famciclovir sustained-release piller:
With famciclovir piller (ball core) (0.9-1.25mm) 1000 weight portions place the bottom spraying type fluidized-bed coating machine, spraying cladding quaternary amine methacrylic acid ester solution, the coating solution prescription is as follows:
Quaternary amine methacrylate 100 weight portions
Polyethylene glycol 6000 10 weight portions
Water 20 weight portions
Magnesium stearate 25 weight portions
Pulvis Talci 25 weight portions
95% ethanol, 1820 weight portions
When quaternary amine methacrylate cladding amount reaches 10% (w/w) of famciclovir pellet weight, clad one deck enteric solubility methacrylate copolymer more outside, the cladding amount of enteric polymer is 5.0% of a famciclovir pellet weight, and (w/w), the prescription of enteric layer coating solution is as follows:
Polyacrylic resin II 25.0 weight portions
Polyacrylic resin III 25.0 weight portions
Polyethylene glycol 6000 5.0 weight portions
Water 10.0 weight portions
Magnesium stearate 12.5 weight portions
Pulvis Talci 12.5 weight portions
95% ethanol, 910.0 weight portions
With piller in 40 ℃ of baking ovens dry 4 hours, the medicament contg of measuring in the piller was 56.8%-65.2% behind the coating EO, and every mass of 1000 kernel 192-220g packs piller in the capsulae vacuus into, makes the famciclovir sustained-release capsule.
After the administration of famciclovir sustained-release capsule oral, blood drug level rises slowly, concentration change is steady, the blood drug level horizontal dimension of 0.5～12h is held between 1.30～3.42 μ g/ml after the administration, the concentration of 12h and 18h almost is more than the twice of ordinary tablet, slow releasing capsule is kept the time of effective penciclovir level in the blood and significantly is longer than ordinary tablet, and both relative bioavailability is suitable.The famciclovir sustained-release capsule can be widely used in treating the antiviral therapy of multiple viral diseases such as herpes zoster and genital herpes and Type B viral hepatitis, viral hepatitis C, for resembling China such hepatitis b virus carrier and the numerous country of patient thereof, acquire a special sense.
Famciclovir sustained-release capsule of the present invention is by control medicine rate of release in vivo, reduced administration number of times, administration every day is 1-2 time when treating banded herpes infection and primary genitalia herpes, each 375mg, reach the equal drug effect of ordinary preparation with administration every day 3 times, and be convenient to patient and regularly take sooner or later, help improving drug compliance, guarantee the due therapeutic effect of medicine.
The capsular release of famciclovir sustained-release is done medium with simulated gastric fluid, simulated intestinal fluid, and the burst size 1.5 hours, 3 hours and 8 hours is respectively more than 10%-30%, 30%-70% and 70%, compares with the famciclovir ordinary tablet, and tangible slow release effect is arranged.The sign content of HPLC method working sample is in the 90.0-110.0% scope.
The capsular removal outer package of famciclovir sustained-release is examined or check under high temperature and super-humid conditions, presents good stable; The famciclovir sustained-release capsule is examined or check under high temperature and super-humid conditions at commercially available back, presents good stable; The famciclovir sustained-release capsule was placed 18 months in commercially available back at ambient temperature, and every index has no significant change, and has good stability.
The specific embodiment
Embodiment 1
A kind of famciclovir sustained-release capsule that is used for antiviral therapy, it is characterized in that: constitute the ball core with adjuvant piller outsourcing famciclovir medicine layer, outside medicine layer, constitute the controlled release internal layer of control drug release by insoluble polymer, outside described controlled release internal layer, clad the controlled release outer coating that constitutes by enteric polymer again, make the famciclovir sustained-release piller, described piller filling constitutes the famciclovir sustained-release capsule in capsule.
By making 1000 calculating of slow releasing capsule, it is composed as follows that various components account for the weight percent of total charges in the every mass of 1000 kernel 192-220g, capsule:
Each component accounts for the percentage by weight of total charges and is in the ball core:
Famciclovir 56.8%
Sucrose 13.1%
Starch 5.1%
Micropowder silica gel 1.1%
Polyvidone (or hypromellose) 2.5%
Each component accounts for the percentage by weight of total charges and is in the controlled release internal layer:
Insoluble polymer (quaternary amine methacrylate or ethyl cellulose) 7.9%
Polyethylene glycol 6000 0.79%
Antiblocking agent (Pulvis Talci) 1.98%
Magnesium stearate 1.98%
Each component accounts for the percentage by weight of total charges and is in the controlled release outer coating:
Enteric polymer (polyacrylic resin II) 2.75%
Enteric polymer (polyacrylic resin III) 2.75%
Plasticizer (polyethylene glycol 6000) 0.55%
Antiblocking agent (Pulvis Talci) 1.36%
The magnesium stearate surplus
Present embodiment adopts the adjuvant piller of sucrose piller for preparation famciclovir ball core, and adjuvant piller diameter is 0.5mm.
The binding agent that preparation famciclovir ball core is selected is a polyvidone, and binding agent is mixed with aqueous solution or organic solvent solution uses.Present embodiment ball core can adopt inertia ball core outsourcing medicine method or extruding round method to produce.
The capsular release of famciclovir sustained-release is done medium with simulated gastric fluid, simulated intestinal fluid, and the burst size 1.5 hours, 3 hours and 8 hours is respectively more than 10%-30%, 30%-70% and 70%.
Embodiment 2
Other are with embodiment 1, but the weight percent of charges is composed as follows in the capsule:
By making 1000 calculating of slow releasing capsule, the weight percent that the interior various components of capsule account for total charges is composed as follows:
Each component accounts for the percentage by weight of total charges and is in the ball core:
Famciclovir 61.00%
Sucrose (or microcrystalline Cellulose) 14.05%
Starch 5.45%
Micropowder silica gel 1.20%
Binding agent: polyvidone (or hypromellose) 2.70%
Each component accounts for the percentage by weight of total charges and is in the controlled release internal layer:
Insoluble polymer (quaternary amine methacrylate or ethyl cellulose) 5.75%
Polyethylene glycol 6000 0.575%
Antiblocking agent (Pulvis Talci) 1.44%
Magnesium stearate 1.44%
Each component accounts for the percentage by weight of total charges and is in the controlled release outer coating:
Enteric polymer (polyacrylic resin II) 2.00%
Enteric polymer (polyacrylic resin III) 2.00%
Plasticizer (polyethylene glycol 6000) 0.40%
Antiblocking agent (Pulvis Talci) 1.00%
The magnesium stearate surplus
Present embodiment adopts the adjuvant piller of sucrose piller for preparation famciclovir ball core, and adjuvant piller diameter is 0.6mm.
The binding agent that preparation famciclovir ball core is selected is a hypromellose, and binding agent is mixed with aqueous solution or organic solvent solution uses.
Embodiment 3
Other are with embodiment 1, but the weight percent of charges is composed as follows in the capsule:
By making 1000 calculating of slow releasing capsule, the weight percent that the interior various components of capsule account for total charges is composed as follows:
Each component accounts for the percentage by weight of total charges and is in the ball core:
Famciclovir 65.20%
Sucrose (or microcrystalline Cellulose) 15.00%
Starch 5.80%
Micropowder silica gel 1.30%
Binding agent: polyvidone 2.90%
Each component accounts for the percentage by weight of total charges and is in the controlled release internal layer:
Insoluble polymer (quaternary amine methacrylate or ethyl cellulose) 3.6%
Polyethylene glycol 6000 0.36%
Antiblocking agent (Pulvis Talci) 0.91%
Magnesium stearate 0.91%
Each component accounts for the percentage by weight of total charges and is in the controlled release outer coating:
Enteric polymer (polyacrylic resin II) 1.26%
Enteric polymer (polyacrylic resin III) 1.26%
Plasticizer (polyethylene glycol 6000) 0.25%
Antiblocking agent (Pulvis Talci) 0.63%
The magnesium stearate surplus
Present embodiment adopts the adjuvant piller of microcrystalline Cellulose for preparation famciclovir ball core, and adjuvant piller diameter is 0.7mm.
The binding agent that preparation famciclovir ball core is selected is a polyvidone.Binding agent makes aqueous solution or organic solvent solution uses.
Embodiment 4
Other are with embodiment 1,
But adopt the adjuvant piller of microcrystalline Cellulose piller for preparation famciclovir ball core, adjuvant piller diameter is 0.5mm.
Embodiment 5
Other are with embodiment 1,
The binding agent that preparation famciclovir ball core is selected is a hypromellose.Binding agent is mixed with aqueous solution or organic solvent solution uses.
Embodiment 6
Other are with embodiment 1,
But adopt the adjuvant piller of microcrystalline Cellulose piller for preparation famciclovir ball core, adjuvant piller diameter is 0.7mm.
Embodiment 7
A kind of capsular production method of famciclovir sustained-release that is used for antiviral therapy, it is characterized in that: constitute the ball core with adjuvant piller outsourcing famciclovir medicine layer, outside medicine layer, constitute the controlled release internal layer of control drug release by insoluble polymer, outside described controlled release internal layer, clad the controlled release outer coating that constitutes by enteric polymer again, make the famciclovir sustained-release piller, described piller filling constitutes the famciclovir sustained-release capsule in capsule;
In the preparation of famciclovir medicine piller: sucrose piller or microcrystalline Cellulose (0.5-0.7mm) 500 weight portions are placed centrifugal coating pelletizing machine, after the start, with 15 weight portions/minute speed spray 5% polyvidone alcoholic solution, 1200 weight portions, simultaneously with 20 weight portions/minute speed be sprinkled into famciclovir powder 1500-1600 weight portion, the medicine piller that makes was placed 50 ℃ of baking ovens dry 4 hours;
In the preparation of famciclovir sustained-release piller:
With famciclovir piller (ball core) (0.9-1.25mm) 1000 weight portions place the bottom spraying type fluidized-bed coating machine, spraying cladding quaternary amine methacrylic acid ester solution, the coating solution prescription is as follows:
Quaternary amine methacrylate 100 weight portions
Polyethylene glycol 6000 10 weight portions
Water 20 weight portions
Magnesium stearate 25 weight portions
Pulvis Talci 25 weight portions
95% ethanol, 1820 weight portions
When quaternary amine methacrylate quaternary amine methacrylate cladding amount reaches 10% (w/w) of famciclovir pellet weight, clad one deck enteric solubility methacrylate copolymer more outside, the cladding amount of enteric polymer is 5.0% of famciclovir piller (ball core) weight, (w/w), the prescription of enteric polymer coating solution is as follows:
Polyacrylic resin II 25.0 weight portions
Polyacrylic resin III 25.0 weight portions
Polyethylene glycol 6000 5.0 weight portions
Water 10.0 weight portions
Magnesium stearate 12.5 weight portions
Pulvis Talci 12.5 weight portions
With piller in 40 ℃ of baking ovens dry 4 hours, the medicament contg of measuring in the piller was 56.8%-65.2% behind the coating EO, and every mass of 1000 kernel 192-220g packs piller in the capsulae vacuus into, makes the famciclovir sustained-release capsule.
Present embodiment adopts the adjuvant piller of microcrystalline Cellulose piller for preparation famciclovir ball core, and adjuvant piller diameter is 0.5-0.7mm.
Embodiment 8
One, famciclovir sustained-release capsule animal pharmacokinetics and bioavailability study (adopting embodiment 2 capsule that obtains)
1, the relative bioavailability experiment that intersects at random behind oral famciclovir sustained-release capsule and the ordinary tablet 750mg of 6 healthy tike single doses shows, this slow releasing capsule blood drug level rises slowly, concentration change is steady, the blood drug level horizontal dimension of 0.5～12h is held between 1.30～3.42 μ g/ml after the administration, the concentration of 12h and 18h almost is more than the twice of ordinary tablet, the C of slow releasing capsule
MaxBe 3.47 ± 0.67 μ g/ml, T
MaxBe 1.92 ± 0.20h, and the C of ordinary tablet
MaxBe 6.00 ± 0.96 μ g/ml, T
MaxBe 0.75 ± 0.19h.Elimination half-life (the T of slow releasing capsule
1/2) prolong to some extent than ordinary tablet, but slow releasing capsule is suitable with the ordinary tablet bioavailability.
2,6 healthy tike multiple doses intersect the stable state pharmacokinetic of oral famciclovir sustained-release capsule and ordinary tablet at random and show that multiple dose continuous oral famciclovir sustained-release capsule and ordinary tablet 750mg every day reach stable state substantially after 3 days.Determination of plasma concentration result by the different time behind the 6th day single administration calculates its main stable state pharmacokinetic parameter: the C of slow releasing capsule
MaxBe 4.79 ± 1.03 μ g/ml, C
MinBe that 3.14 ± 1.16 μ g/ml, R (peak-to-valley ratio) are 1.64 ± 0.43, C
AvBe that 3.04 ± 0.92 μ g/ml, DF (fluctuation degree) are 58.2 ± 18.9%; The C of ordinary tablet
MaxBe 6.66 ± 1.27 μ g/ml, C
MinBe that 2.12 ± 0.79 μ g/ml, R (peak-to-valley ratio) are 3.44 ± 1.18, C
AvBe that 2.79 ± 0.78 μ g/ml, DF (fluctuation degree) are 167.1 ± 27.0%, this slow releasing capsule of results suggest has sustained releasing character.
Present embodiment shows:
6 healthy tike single doses intersect the determination of plasma concentration and the bioavailability study result of the different time behind oral famciclovir sustained-release capsule and the famciclovir ordinary tablet 750mg and show, this slow releasing capsule can make blood drug level keep maintenance level in a long time, the concentration of administration 0.5～12h is between 1.30～3.42 μ g/ml, the concentration of 12h and 18h is kept the time of penciclovir concentration＞IC50 (for HSV) in the blood and is longer than ordinary tablet almost at more than 2 times of ordinary tablet; Relative bioavailability is calculated and is shown that slow releasing capsule is suitable with ordinary tablet, and slow releasing capsule AUC/IC50 value and ordinary tablet do not have significant difference.
6 healthy tike multiple doses intersect the stable state pharmacokinetic of oral administration famciclovir sustained-release capsule and ordinary tablet and show, the peak-to-valley ratio of slow releasing capsule is significantly less than ordinary tablet (P＜0.01), the fluctuation degree is starkly lower than ordinary tablet (P＜0.01), demonstrate sustained releasing character, the prompting said preparation is a slow releasing preparation.
The preparation of embodiment 9 famciclovir pillers (ball core)
Sucrose piller (0.7-0.8mm) 500g places centrifugal comminutor, after the start, sprays 5% polyvidone alcoholic solution 1200g, is sprinkled into famciclovir powder 1500g with suitable speed, the medicine piller that makes simultaneously.Piller was placed 50 ℃ of baking ovens dry 4 hours.
The preparation of embodiment 10 famciclovir sustained-release pillers
Famciclovir piller (ball core) (0.8-0.9mm) 200g places the bottom spraying type fluidized-bed coating machine, spraying cladding quaternary amine methacrylic acid ester solution, and the coating solution prescription is as follows:
Quaternary amine methacrylate 50.0g
Triethyl citrate 5.0g
Pulvis Talci 25.0g
95% ethanol 920.0g
In the coating process, sampling when polymer cladding amount is 12.5% (w/w), 17.0% (w/w) and 23.0% (w/) is for drug release determination.The result is as follows:
| Polymer cladding amount (%, w/w) | Release (%) | ||
| 1 hour | 2 hours | 4 hours | |
| 12.5 | 52.6 | 78.7 | 92.7 |
| 17.0 | 38.5 | 72.3 | 90.0 |
| 23.0 | 25.5 | 59.0 | 82.4 |
The preparation of embodiment 11 famciclovir sustained-release pillers
Famciclovir piller (ball core) (0.8-0.9mm) 200g places the bottom spraying type fluidized-bed coating machine, spraying cladding quaternary amine methacrylic acid ester solution, and the coating solution prescription is as follows:
Quaternary amine methacrylate 50.0g
Triethyl citrate 5.0g
Pulvis Talci 12.5g
Magnesium stearate 12.5g
95% ethanol 920.0g
In the coating process, sampling when polymer cladding amount is 5.0% (w/w) and 6.0% (w/w) is for drug release determination.The result is as follows:
| Polymer cladding amount (%, w/w) | Release (%) | ||
| 1 hour | 2 hours | 4 hours | |
| 5.0 | 35.8 | 57.4 | 76.1 |
| 6.0 | 28.5 | 48.9 | 67.7 |
Compare as seen by embodiment 10 and embodiment 11: in coating, add hydrophobic magnesium stearate, but the blocking medicine rate of release.
The preparation of embodiment 12 famciclovir sustained-release pillers
Famciclovir piller (ball core) (0.8-0.9mm) 200g places the bottom spraying type fluidized-bed coating machine, spraying cladding quaternary amine methacrylic acid ester solution, and the coating solution prescription is as follows:
Quaternary amine methacrylate 50.0g
Polyethylene glycol 6000 5.0g
Water 10.0g
Magnesium stearate 12.5g
Pulvis Talci 12.5g
95% ethanol 910.0g
In the coating process, sampling when polymer cladding amount is 6.0% (w/w) is for drug release determination.The result is as follows:
| Polymer cladding amount (%, w/w) | Release (%) | |||||
| 1 hour | 2 hours | 3 hours | 4 hours | 6 hours | 8 hours | |
| 6.0 | 24.3 | 45.3 | 56.9 | 64.7 | 74.7 | 81.2 |
The present embodiment plasticizer is used polyethylene glycol 6000 instead, but the release of gained slow-release pill is similar to embodiment 11.
The preparation of embodiment 13 famciclovir sustained-release pillers
Famciclovir piller (ball core) (1.25-1.4mm) 200g places the bottom spraying type fluidized-bed coating machine, spraying cladding quaternary amine methacrylic acid ester solution, and the coating solution prescription is as follows:
Quaternary amine methacrylate 50.0g
Polyethylene glycol 6000 5.0g
Water 10.0g
Magnesium stearate 12.5g
Pulvis Talci 12.5g
95% ethanol 910.0g
In the coating process, sampling when polymer cladding amount is 4.0% (w/w) is for drug release determination.The result is as follows:
| Polymer cladding amount (%, w/w) | Release (%) | |||||
| 1 hour | 2 hours | 3 hours | 4 hours | 6 hours | 8 hours | |
| 4.0 | 25.6 | 47.2 | 58.8 | 65.3 | 78.7 | 88.6 |
The used medicine piller granularity of the manner is bigger, and total surface area reduces, and reaches the required polymer volume of same release and also reduces thereupon.
Claims (6)
1, a kind of famciclovir sustained-release capsule that is used for antiviral therapy, it is characterized in that: constitute the ball core with adjuvant piller outsourcing famciclovir medicine layer, outside medicine layer, constitute the controlled release internal layer of control drug release by insoluble polymer, outside described controlled release internal layer, clad the controlled release outer coating that is made of enteric polymer again, make the famciclovir sustained-release piller, described piller filling is in capsule, constitute the famciclovir sustained-release capsule
By making 1000 calculating of slow releasing capsule, every mass of 1000 kernel 192-220g packs piller in the capsulae vacuus into, makes the famciclovir sustained-release capsule, and it is composed as follows that various components account for the weight percent of total charges in the capsule:
Each component accounts for the percentage by weight of total charges and is in the ball core:
Famciclovir 56.8%-65.2%
Sucrose (or microcrystalline Cellulose) 13.1%-15.0%
Starch 5.1%-5.8%
Micropowder silica gel 1.1%-1.3%
Binding agent: polyvidone (or hypromellose) 2.5%-2.9%
Each component accounts for the percentage by weight of total charges and is in the controlled release internal layer:
Insoluble polymer (quaternary amine methacrylate or ethyl cellulose) 3.6%-7.9%
Polyethylene glycol 6000 0.36%0.79%
Antiblocking agent (Pulvis Talci) 0.91%-1.98%
Magnesium stearate 0.91%-1.98%
Each component accounts for the percentage by weight of total charges and is in the controlled release outer coating:
Enteric polymer (polyacrylic resin II) 1.26%-2.75%
Enteric polymer (polyacrylic resin III) 1.26%-2.75%
Plasticizer (polyethylene glycol 6000) 0.25%-0.55%
Antiblocking agent (Pulvis Talci) 0.63%-1.36%
The magnesium stearate surplus
The capsular famciclovir sustained-release piller of famciclovir sustained-release is done medium with simulated gastric fluid, simulated intestinal fluid, and the release scope 1.5 hours, 3 hours and 8 hours is respectively: more than 10%-30%, the 30%-70% and 70%,
Adopt sucrose piller or the microcrystalline Cellulose piller adjuvant piller for preparation famciclovir ball core, adjuvant piller diameter is 0.5-0.7mm,
The binding agent that preparation famciclovir ball core is selected is polyvidone or hypromellose, and binding agent is mixed with aqueous solution or organic solvent solution uses,
The controlled release internal layer polymer of cladding is selected quaternary amine methacrylate or ethyl cellulose outside the famciclovir piller, adopt polymer to be dissolved in the solution of organic solvent, or the aqueous dispersion of polymer, clad the enteric polymer as controlled release outer coating outside the controlled release internal layer again, these enteric polymer are selected from methylmethacrylate copolymer, ethyl methacrylate copolymers or hypromellose phthalate ester.
2, a kind of famciclovir sustained-release capsule that is used for antiviral therapy according to claim 1 is characterized in that: the weight percent that the interior various components of capsule account for total charges is composed as follows:
Each component accounts for the percentage by weight of total charges and is in the ball core:
Famciclovir 56.8%
Sucrose 13.1%
Starch 5.1%
Micropowder silica gel 1.1%
Binding agent: polyvidone (or hypromellose) 2.5%
Each component accounts for the percentage by weight of total charges and is in the controlled release internal layer:
Insoluble polymer (quaternary amine methacrylate or ethyl cellulose) 7.9%
Polyethylene glycol 6000 0.79%
Antiblocking agent (Pulvis Talci) 1.98%
Magnesium stearate 1.98%
Each component accounts for the percentage by weight of total charges and is in the controlled release outer coating:
Enteric polymer (polyacrylic resin II) 2.75%
Enteric polymer (polyacrylic resin III) 2.75%
Plasticizer (polyethylene glycol 6000) 0.55%
Antiblocking agent (Pulvis Talci) 1.36%
The magnesium stearate surplus
Adopt the adjuvant piller of sucrose piller for preparation famciclovir ball core, adjuvant piller diameter is 0.5mm,
The binding agent that preparation famciclovir ball core is selected is a polyvidone, and binding agent is mixed with aqueous solution or organic solvent solution uses.
3, a kind of famciclovir sustained-release capsule that is used for antiviral therapy according to claim 1 is characterized in that: the weight percent that the interior various components of capsule account for total charges is composed as follows:
Each component accounts for the percentage by weight of total charges and is in the ball core:
Famciclovir 61.00%
Sucrose (or microcrystalline Cellulose) 14.05%
Starch 5.45%
Micropowder silica gel 1.20%
Polyvidone (or hypromellose) 2.70%
Each component accounts for the percentage by weight of total charges and is in the controlled release internal layer:
Insoluble polymer (quaternary amine methacrylate or ethyl cellulose) 5.75%
Polyethylene glycol 6000 0.575%
Antiblocking agent (Pulvis Talci) 1.44%
Magnesium stearate 1.44%
Each component accounts for the percentage by weight of total charges and is in the controlled release outer coating:
Enteric polymer (polyacrylic resin II) 2.00%
Enteric polymer (polyacrylic resin III) 2.00%
Plasticizer (polyethylene glycol 6000) 0.40%
Antiblocking agent (Pulvis Talci) 1.00%
The magnesium stearate surplus
Adopt the adjuvant piller of sucrose piller for preparation famciclovir ball core, adjuvant piller diameter is 0.6mm,
The binding agent that preparation famciclovir ball core is selected is a hypromellose, and binding agent is mixed with aqueous solution or organic solvent solution uses.
4, a kind of famciclovir sustained-release capsule that is used for antiviral therapy according to claim 1 is characterized in that: the weight percent that the interior various components of capsule account for total charges is composed as follows:
Each component accounts for the percentage by weight of total charges and is in the ball core:
Famciclovir 65.2%
Sucrose (or microcrystalline Cellulose) 15.00%
Starch 5.80%
Micropowder silica gel 1.30%
Binding agent: polyvidone 2.90%
Each component accounts for the percentage by weight of total charges and is in the controlled release internal layer:
Insoluble polymer (quaternary amine methacrylate or ethyl cellulose) 3.60%
Polyethylene glycol 6000 0.36%
Antiblocking agent (Pulvis Talci) 0.91%
Magnesium stearate 0.91%
Each component accounts for the percentage by weight of total charges and is in the controlled release outer coating:
Enteric polymer (polyacrylic resin II) 1.25%
Enteric polymer (polyacrylic resin III) 1.25%
Plasticizer (polyethylene glycol 6000) 0.25%
Antiblocking agent (Pulvis Talci) 0.63%
The magnesium stearate surplus
It is the adjuvant piller of preparation famciclovir ball core that the present invention adopts microcrystalline Cellulose, and adjuvant piller diameter is 0.7mm,
The binding agent that preparation famciclovir ball core is selected is a polyvidone, and binding agent is mixed with aqueous solution or organic solvent solution uses.
5, a kind of capsular production method of famciclovir sustained-release that is used for antiviral therapy, it is characterized in that: with adjuvant piller outsourcing famciclovir medicine layer structure ball core, outside medicine layer, constitute the controlled release internal layer of control drug release by insoluble polymer, outside described controlled release internal layer, clad the controlled release outer coating that constitutes by enteric polymer again, make the famciclovir sustained-release piller, described piller filling constitutes the famciclovir sustained-release capsule in capsule;
In the preparation of ball core: sucrose piller or microcrystalline Cellulose (0.5-0.7mm) 500 weight portions are placed centrifugal coating pelletizing machine, after the start, with 15 weight portions/minute speed spray 5% polyvidone alcoholic solution, 1200 weight portions, simultaneously with 20 weight portions/minute speed be sprinkled into famciclovir powder 1500-1600 weight portion, the medicine ball core that makes was placed 50 ℃ of baking ovens dry 4 hours;
In the preparation of famciclovir sustained-release piller:
Ball core (0.9-1.25mm) 1000 weight portions are placed the bottom spraying type fluidized-bed coating machine, spraying cladding quaternary amine methacrylic acid ester solution, the coating solution prescription is as follows:
Quaternary amine methacrylate 100 weight portions
Polyethylene glycol 6000 10 weight portions
Water 20 weight portions
Magnesium stearate 25 weight portions
Pulvis Talci 25 weight portions
95% ethanol, 1820 weight portions
When quaternary amine methacrylate cladding amount reaches 10% (w/w) of famciclovir pellet weight, clad one deck enteric solubility methacrylate copolymer more outside, the cladding amount of enteric polymer is 5.0% of a ball core weight, and (w/w), the prescription of enteric layer coating solution is as follows:
Polyacrylic resin II 25.0 weight portions
Polyacrylic resin III 25.0 weight portions
Polyethylene glycol 6000 5.0 weight portions
Water 10.0 weight portions
Magnesium stearate 12.5 weight portions
Pulvis Talci 12.5 weight portions
95% ethanol, 910.0 weight portions
With piller in 40 ℃ of baking ovens dry 4 hours, the medicament contg of measuring in the piller was 56.8%-65.2% behind the coating EO, every mass of 1000 kernel 192-220g,, piller is packed in the capsulae vacuus, make the famciclovir sustained-release capsule.
6, a kind of capsular production method of famciclovir sustained-release that is used for antiviral therapy according to claim 5 is characterized in that: described ball core adopts inertia ball core outsourcing medicine method or extruding round method to produce.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410027929XA CN100406014C (en) | 2004-06-30 | 2004-06-30 | Famciclovir slow-releasing capsule for anti-virus treatment and its producing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410027929XA CN100406014C (en) | 2004-06-30 | 2004-06-30 | Famciclovir slow-releasing capsule for anti-virus treatment and its producing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1714793A true CN1714793A (en) | 2006-01-04 |
| CN100406014C CN100406014C (en) | 2008-07-30 |
Family
ID=35821155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410027929XA Expired - Lifetime CN100406014C (en) | 2004-06-30 | 2004-06-30 | Famciclovir slow-releasing capsule for anti-virus treatment and its producing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100406014C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103462930A (en) * | 2013-09-05 | 2013-12-25 | 南京正亮医药科技有限公司 | Ganciclovir capsule preparation and preparation method thereof |
| CN103479782A (en) * | 2013-08-30 | 2014-01-01 | 贵阳新天药业股份有限公司 | Slow-release capsule and preparation method thereof |
| CN103622934A (en) * | 2013-11-13 | 2014-03-12 | 青海互丰农业科技集团有限公司 | Sustained-release cordycepin capsule and preparation method thereof |
| CN104622891A (en) * | 2014-09-22 | 2015-05-20 | 青海大学 | Sustained-release pellets prepared from Tibetan medicine Zhaxun and sustained-release capsules |
| CN109288802A (en) * | 2018-10-25 | 2019-02-01 | 安徽鼎旺医药有限公司 | A kind of preparation method of spherical shape famciclovir sustained-release capsule |
| CN115530377A (en) * | 2022-10-13 | 2022-12-30 | 扬州市扬大康源乳业有限公司 | Slow-release probiotics and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1179717A (en) * | 1995-02-06 | 1998-04-22 | 阿斯特拉公司 | Novel pharmaceutical composition |
-
2004
- 2004-06-30 CN CNB200410027929XA patent/CN100406014C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479782A (en) * | 2013-08-30 | 2014-01-01 | 贵阳新天药业股份有限公司 | Slow-release capsule and preparation method thereof |
| CN103479782B (en) * | 2013-08-30 | 2015-10-07 | 贵阳新天药业股份有限公司 | A kind of slow releasing capsule and preparation method thereof |
| CN103462930A (en) * | 2013-09-05 | 2013-12-25 | 南京正亮医药科技有限公司 | Ganciclovir capsule preparation and preparation method thereof |
| CN103622934A (en) * | 2013-11-13 | 2014-03-12 | 青海互丰农业科技集团有限公司 | Sustained-release cordycepin capsule and preparation method thereof |
| CN104622891A (en) * | 2014-09-22 | 2015-05-20 | 青海大学 | Sustained-release pellets prepared from Tibetan medicine Zhaxun and sustained-release capsules |
| CN109288802A (en) * | 2018-10-25 | 2019-02-01 | 安徽鼎旺医药有限公司 | A kind of preparation method of spherical shape famciclovir sustained-release capsule |
| CN115530377A (en) * | 2022-10-13 | 2022-12-30 | 扬州市扬大康源乳业有限公司 | Slow-release probiotics and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100406014C (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101036633A (en) | Enteric coated omeprazole pellets capsule and the preparing method thereof | |
| CN1682719A (en) | Enteric soluble coating slow releasing tablet containing huperzine A and preparing method | |
| CN1929821A (en) | Pharmaceutical composition comprising pimobendan | |
| CN1990484A (en) | Silybin esters derivatives and preparation and use thereof | |
| CN1642530A (en) | Compressed tablets comprising microcapsules with modified release | |
| CN101080218A (en) | Method for producing coated drugs having a stable profile for the release of active ingredients | |
| CN1655767A (en) | Coated particles with prolonged release and tablets containing same | |
| CN1527706A (en) | Pharmaceutical compositions containing terbinafin and use thereof | |
| CN1631247A (en) | Health food with hypoxia preventing and anti-fatigue function and preparation technique thereof | |
| CN101045044A (en) | Thipronin enteric-coated delayed-release agent | |
| CN1931143A (en) | Orally taken control released trimetazidine medicine composition | |
| CN1883459A (en) | Enteric coated preparation of entecavir and preparation method thereof | |
| CN1714793A (en) | Famciclovir slow-releasing capsule for anti-virus treatment and its producing method | |
| CN101028254A (en) | Sustaining agent of Duosuo theosine and its preparation | |
| CN1698594A (en) | Tiopronin slow releasing preparation | |
| CN1034134A (en) | Be used for the treatment of compositions and preparation method that back virus merges cancer | |
| CN1235544A (en) | Controlled release dosage form of R-(Z)-alpha-methoxyimino-alpha-(1-azabicyclo 2,2 oct-c-yl) acetonitrile monohydrochloride | |
| CN1718239A (en) | Oral adhering piece for treating oral exulceratio, and its prepn. method | |
| CN1857288A (en) | Slow released compound preparation of glycyrrhizic acid and glycyrrhizinate and its preparing process | |
| CN1698888A (en) | Oral cavity plastering sheet of interferon and its preparation method | |
| CN1899287A (en) | Slow release medicinal composition for treating anxiety and its preparing method | |
| CN1679901A (en) | Compound preparation of Jianganling for liver and its making method | |
| CN1265793C (en) | Oral compound levocetirizine pseudoephedrine formulation and its preparation | |
| CN1895218A (en) | Pyrrolechrisxi and its sodium-salt eye-gel preparation and its making method | |
| CN1279920C (en) | Slow release preparation of diammonium glycyrrhizate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20080730 |
|
| CX01 | Expiry of patent term |